Status:

COMPLETED

Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in Tanzania

Lead Sponsor:

University of Copenhagen

Collaborating Sponsors:

National Institute for Medical Research, Tanzania

London School of Hygiene and Tropical Medicine

Conditions:

Malaria, Falciparum

HIV Infections

Eligibility:

All Genders

15-60 years

Phase:

PHASE4

Brief Summary

As HIV/AIDS is spreading in malaria-endemic countries, many patients here will need concomitant treatment for both infections. Effective combination treatments are available for both malaria (artemisi...

Eligibility Criteria

Inclusion

  • HIV-positive and HIV-negative patients with confirmed P. falciparum infection in the presence of either measured fever (\> 37.5°C) or a history of fever within the previous 24 hours; for HIV-positive patients also afebrile patients are eligible in the presence of other symptoms of malaria (e.g., coughing, diarrhea, headache, nausea, body weakness, body pain).
  • Not being pregnant or lactating.
  • Absence of history of clinically significant hypersensitivity reactions to any of the study medicines being evaluated.
  • For HIV-positive patients on cART, successful adherence to treatment without prominent adverse events for a period of a minimum of six weeks prior to the date of enrollment will be required.
  • Easy access to the health facility (travel time \< 1 hour) and the ability to attend the stipulated follow-up visits.
  • Informed consent provided by the patient or by a parent/guardian

Exclusion

  • Patients below body weight of 10 kilograms (for under fives).
  • Existence of underlying chronic severe illness (e.g., cardiac, renal or hepatic disease).
  • No use within the previous four weeks prior to enrollment of any other antimalarial or other drug with antimalarial activity (with the exception of drugs required as part of standard treatment of HIV/AIDS, e.g., sulfamethoxazole and trimethoprim).

Key Trial Info

Start Date :

July 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2013

Estimated Enrollment :

830 Patients enrolled

Trial Details

Trial ID

NCT00885287

Start Date

July 1 2009

End Date

January 1 2013

Last Update

January 16 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Muheza Designated District Hospital

Muheza, Tanga, Tanzania